(Thursday, 7/16/2020) 1:00 PM - 3:00 PM [Eastern Time (GMT-4)]
Room: Track 2
The use of radionuclide therapy is becoming more prevalent but there is not yet a consensus on reporting the received radiation dose to tumors and organs at risk.
This session will provide an overview of necessary requirements for harmonization of imaging protocols to be used to determine the received dose along with the steps required for calculating and reporting the received radiation dose to tumors and healthy tissues. Uncertainties in dose calculation methodologies will be discussed.
The clinical impact of radionuclide therapies may be increased when pre-treatment imaging studies can be used to predict the received absorbed dose from the therapy and when these therapies are combined with other therapeutic options (e.g. immunotherapy). Mathematical models to improve the prediction of absorbed dose from 90Y microspheres will be introduced and combination therapy of radionuclide therapy and immunotherapy will be highlighted.
Learning Objectives:
1. Understand uncertainties in SPECT/CT and PET/CT and how this may impact reported radiation dose from radionuclide therapies.
2. Understand the necessary steps required for reporting and calculating received radiation dose from radionuclide therapies.
3. Understand the potential of mathematical models to improve the predictive value of pretreatment 99mTc-MAA SPECT/CT in 90Y microsphere treatment.
Handouts
Keywords
Not Applicable / None Entered.
Taxonomy
Not Applicable / None Entered.
Contact Email
